FOR US HEALTHCARE PROFESSIONALS ONLY
| INVEGA TRINZA® (n=195) | INVEGA HAFYERA® (n=423) | |
|---|---|---|
| Normal to high | 3% | 4% |
| Impaired glucose tolerance to high | 4% | 5% |
| Normal/impaired glucose tolerance to high | 7% | 9% |
| <126 mg/dL to ≥140 mg/dL | 4% | 5% |
| <126 mg/dL to ≥200 mg/dL | 0% | 1% |
| <126 mg/dL to ≥300 mg/dL | 0% | <1% |
Table reflects subjects with paired fasting data (baseline and any post-baseline assessment).
Using the conversion factor (1 mg/dL=0.05551 mmol/L), the ADA-specified limits are as follows:
Normal: <100 mg/dL (<5.551 mmol/L)
Impaired: ≥100 mg/dL (≥5.551 mmol/L) to <126 mg/dL (<6.994 mmol/L)
High: ≥126 mg/dL (≥6.994 mmol/L)
126 mg/dL=6.994 mmol/L; 140 mg/dL=7.771 mmol/L; 200 mg/dL=11.102 mmol/L; 300 mg/dL=16.653 mmol/L
ADA=American Diabetes Association.
Hyperglycemia and diabetes mellitus1
| INVEGA TRINZA® (n=194) | INVEGA HAFYERA® (n=423) | |
|---|---|---|
| Fasting cholesterol (mg/dL): <200 mg/dL to ≥240 mg/dL | 2 (1%) | 3 (0.7%) |
| Fasting HDL cholesterol (mg/dL): ≥40 mg/dL to <40 mg/dL | 28 (14%) | 55 (13%) |
| Fasting LDL cholesterol (mg/dL): <100 mg/dL to ≥160 mg/dL | 1 (0.5%) | 2 (0.5%) |
| Fasting triglycerides (mg/dL): <150 mg/dL to ≥200 mg/dL | 22 (11%) | 22 (5%) |
For each fasting parameter, patients with both baseline (DB) record and any post-baseline (DB) record during the double-blind phase are included in the denominator.
DB=double-blind phase; HDL=high-density lipoprotein; LDL=low-density lipoprotein.
Dyslipidemia1
Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
Reference: 1. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Najarian D, Turkoz I, Knight k, et al. Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia. Int J Neuropsychopharmacol. 2023;26(8):537-544.
Back to Top